Published May 1, 2013 - More info
Serine palmitoyltransferase (SPT) is the first and rate-limiting enzyme of the de novo biosynthetic pathway of sphingomyelin (SM). Both SPT and SM have been implicated in the pathogenesis of atherosclerosis, the development of which is driven by macrophages; however, the role of SPT in macrophage-mediated atherogenesis is unknown. To address this issue, we have analyzed macrophage inflammatory responses and reverse cholesterol transport, 2 key mediators of atherogenesis, in SPT subunit 2–haploinsufficient (
Mahua Chakraborty, Caixia Lou, Chongmin Huan, Ming-Shang Kuo, Tae-Sik Park, Guoqing Cao, Xian-Cheng Jiang
Original citation: J. Clin. Invest. 2013;123(4):1784–1797. doi:10.1172/JCI60415.
Citation for this erratum: J. Clin. Invest. 2013;123(5):2332. doi:10.1172/JCI70146.
During the processing of this manuscript, the Western blot in Figure 3D was labeled incorrectly. The correct figure is below.
The JCI regrets the error.